Status:
RECRUITING
LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Lead Sponsor:
Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Conditions:
Lung Cancer
Eligibility:
All Genders
18-125 years
Brief Summary
This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molec...
Detailed Description
The identification of driver-mutations, whose gene product can be specifically inhibited by targeted therapies, has markedly changed the diagnostic and therapeutic landscape for this tumor entity, lea...
Eligibility Criteria
Inclusion
- Informed consent
- Histologically confirmed lung cancer
- Age ≥ 18 years
- Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
Exclusion
- \-
Key Trial Info
Start Date :
April 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2030
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04733430
Start Date
April 17 2020
End Date
April 1 2030
Last Update
March 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie
Vienna, Austria, 1160